Put Options

8 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$2.73 - $4.73 $30,849 - $53,449
-11,300 Reduced 14.69%
65,600 $194,000
Q1 2024

May 15, 2024

SELL
$4.29 - $5.97 $230,373 - $320,589
-53,700 Reduced 41.12%
76,900 $348,000
Q4 2023

Feb 14, 2024

BUY
$3.91 - $5.93 $195,500 - $296,500
50,000 Added 62.03%
130,600 $745,000
Q3 2023

Nov 14, 2023

BUY
$4.6 - $7.95 $25,299 - $43,725
5,500 Added 7.32%
80,600 $370,000
Q2 2023

Aug 14, 2023

BUY
$5.66 - $7.59 $21,508 - $28,842
3,800 Added 5.33%
75,100 $485,000
Q1 2023

May 15, 2023

SELL
$7.31 - $11.18 $929,832 - $1.42 Million
-127,200 Reduced 64.08%
71,300 $537,000
Q4 2022

Feb 14, 2023

SELL
$9.48 - $14.52 $194,340 - $297,660
-20,500 Reduced 9.36%
198,500 $2.01 Million
Q3 2022

Nov 14, 2022

SELL
$9.2 - $13.68 $684,480 - $1.02 Million
-74,400 Reduced 25.36%
219,000 $2.17 Million

Others Institutions Holding ABCL

About AbCellera Biologics Inc.


  • Ticker ABCL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 285,139,008
  • Market Cap $681M
  • Description
  • AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...
More about ABCL
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.